242 related articles for article (PubMed ID: 9339201)
1. [P53 mutations, asset or disadvantage for cancer chemotherapy].
Jacquemin-Sablon A
Bull Cancer; 1997 Jul; 84(7):741-6. PubMed ID: 9339201
[TBL] [Abstract][Full Text] [Related]
2. p53 and response to chemotherapy and radiotherapy.
Ruley HE
Important Adv Oncol; 1996; ():37-56. PubMed ID: 8791127
[No Abstract] [Full Text] [Related]
3. [Tumor suppressor gene p53: mechanisms of action in cell proliferation and death].
Mendoza-Rodríguez CA; Cerbón MA
Rev Invest Clin; 2001; 53(3):266-73. PubMed ID: 11496714
[TBL] [Abstract][Full Text] [Related]
4. [Tumor suppressor p53 gene: a potential target for cancer therapy?].
Soussi T
Bull Cancer; 1997 Jul; 84(7):753-6. PubMed ID: 9339203
[No Abstract] [Full Text] [Related]
5. Role of p53 and p16 gene alterations in determining response to concurrent paclitaxel and radiation in solid tumor.
King TC; Estalilla OC; Safran H
Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):4-11. PubMed ID: 10210535
[TBL] [Abstract][Full Text] [Related]
6. [Cell cycle regulation after exposure to ionizing radiation].
Teyssier F; Bay JO; Dionet C; Verrelle P
Bull Cancer; 1999 Apr; 86(4):345-57. PubMed ID: 10341340
[TBL] [Abstract][Full Text] [Related]
7. Induction of apoptosis and cell cycle-specific change in expression of p53 in normal lymphocytes and MOLT-4 leukemic cells by nitrogen mustard.
Bhatia U; Danishefsky K; Traganos F; Darzynkiewicz Z
Clin Cancer Res; 1995 Aug; 1(8):873-80. PubMed ID: 9816057
[TBL] [Abstract][Full Text] [Related]
8. The dual role of mutant p53 protein in chemosensitivity of human cancers.
Mueller H; Eppenberger U
Anticancer Res; 1996; 16(6B):3845-8. PubMed ID: 9042268
[TBL] [Abstract][Full Text] [Related]
9. A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line.
Cinti C; Claudio PP; Luca AD; Cuccurese M; Howard CM; D'Esposito M; Paggi MG; Sala DL; Azzoni L; Halazonetis TD; Giordano A; Maraldi NM
Oncogene; 2000 Oct; 19(44):5098-105. PubMed ID: 11042698
[TBL] [Abstract][Full Text] [Related]
10. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
[TBL] [Abstract][Full Text] [Related]
11. p53 apoptotic response to DNA damage dependent on bcl2 but not bax in head and neck squamous cell carcinoma lines.
Crowe DL; Sinha UK
Head Neck; 2006 Jan; 28(1):15-23. PubMed ID: 16302195
[TBL] [Abstract][Full Text] [Related]
12. Bcl2-negative MCF7 cells overexpress p53: implications for the cell cycle and sensitivity to cytotoxic drugs.
Poliseno L; Mariani L; Collecchi P; Piras A; Zaccaro L; Rainaldi G
Cancer Chemother Pharmacol; 2002 Aug; 50(2):127-30. PubMed ID: 12172977
[TBL] [Abstract][Full Text] [Related]
13. [Antioncogene p53 and apoptosis response: new hypotheses on the molecular bases of tumor resistance to radiotherapy].
Corvò R
Radiol Med; 1996 Sep; 92(3):298-302. PubMed ID: 8975319
[TBL] [Abstract][Full Text] [Related]
14. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.
Reles A; Wen WH; Schmider A; Gee C; Runnebaum IB; Kilian U; Jones LA; El-Naggar A; Minguillon C; Schönborn I; Reich O; Kreienberg R; Lichtenegger W; Press MF
Clin Cancer Res; 2001 Oct; 7(10):2984-97. PubMed ID: 11595686
[TBL] [Abstract][Full Text] [Related]
15. Retinoic acid-mediated G1-S-phase arrest of normal human mammary epithelial cells is independent of the level of p53 protein expression.
Seewaldt VL; Dietze EC; Johnson BS; Collins SJ; Parker MB
Cell Growth Differ; 1999 Jan; 10(1):49-59. PubMed ID: 9950218
[TBL] [Abstract][Full Text] [Related]
16. Relaxed cell-cycle arrests and propagation of unrepaired chromosomal damage in cancer cell lines with wild-type p53.
Olivier M; Bautista S; Vallès H; Theillet C
Mol Carcinog; 1998 Sep; 23(1):1-12. PubMed ID: 9766432
[TBL] [Abstract][Full Text] [Related]
17. Endogenous p53 regulation and function in early stage Friend virus-induced tumor progression differs from that following DNA damage.
Kelley LL; Hicks GG; Hsieh FF; Prasher JM; Green WF; Miller MD; Eide EJ; Ruley HE
Oncogene; 1998 Sep; 17(9):1119-30. PubMed ID: 9764822
[TBL] [Abstract][Full Text] [Related]
18. p53 mutation heterogeneity in cancer.
Soussi T; Lozano G
Biochem Biophys Res Commun; 2005 Jun; 331(3):834-42. PubMed ID: 15865939
[TBL] [Abstract][Full Text] [Related]
19. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
[TBL] [Abstract][Full Text] [Related]
20. Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215.
Georges SA; Biery MC; Kim SY; Schelter JM; Guo J; Chang AN; Jackson AL; Carleton MO; Linsley PS; Cleary MA; Chau BN
Cancer Res; 2008 Dec; 68(24):10105-12. PubMed ID: 19074876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
